Aug 5, 2026 · 6 min
AI spending lifts Lilly while dialysis miss hits DaVita
SpaceX Falls, Eli Lilly Jumps, Davita Slides as US Dialysis Revenue Misses Estimates
The episode shows how investor reactions are splitting across AI investment, weight-loss drug demand, and healthcare revenue execution.
- 1SpaceX is increasing capital expenditures on artificial intelligence, putting spending at the center of its earnings story.
- 2Eli Lilly raised its sales guidance after strong second-quarter results and continued momentum from its weight-loss drug franchise.
- 3DaVita shares fell after US dialysis revenue missed estimates, while airlines use AI to adjust seat prices in real time.
Don't miss
Avalon Purnell contrasts Eli Lilly’s guidance boost with DaVita’s stock decline after a US dialysis revenue miss.
The brief
SpaceX’s earnings story is increasingly defined by capital spending on artificial intelligence, making investment intensity a key market signal.
Bloomberg News equities reporter Avalon Purnell explains why Eli Lilly raised its sales guidance after strong second-quarter results and weight-loss drug demand.
DaVita moved lower after missing estimates for US dialysis revenue, showing how a specific operating shortfall can quickly reshape a healthcare stock’s outlook.
The episode closes with airlines using artificial intelligence to adjust seat prices in real time, extending the market story from corporate spending to consumer pricing.
What was said on this episode
13 statements · 5 positive · 7 negative · 1 neutral
SpaceX’s capital expenditure levels concern investors.
“the capex levels are a major concern for investors”
Listen at 1:24
SpaceX will require over $400 billion in funding to break even.
“SpaceX will need more than $400 billion in funding to hit break even.”
Listen at 1:28
SpaceX’s lockup expiration is contributing to current stock weakness.
“the lockup expiration is also contributing to stock weakness today.”
Listen at 1:34
SpaceX shares worth $101 billion will become tradable tomorrow.
“those $101 billion worth of shares become available for trading tomorrow.”
Listen at 1:39
SpaceX’s stock remains well below its $135 IPO price.
“this stock that remains well below the 135ipo price.”
Listen at 1:45
Eli Lilly’s strong second-quarter results increased its 2026 sales guidance.
“the firm's better than expected second quarter results led to a boost in 2026 sales guidance.”
Listen at 1:59
Eli Lilly’s results will ease fears that the obesity-drug boom is slowing.
“these results are definitely going to assuage some fears from investors that the obesity drug boom is starting to slow down”
Listen at 2:18
DaVita’s US dialysis revenue missed estimates.
“their US dialysis revenue missed estimates.”
Listen at 2:42
DaVita’s US dialysis EBIT continues to miss expectations.
“the US Dialysis EBIT continues to fall short”
Listen at 2:54
AI seat pricing helps airlines capture revenue and reduce bargain-fare gaps.
“helping capture more revenue while shrinking pricing gaps that once allowed travelers to find bargain fares.”
Listen at 4:04
Machine-learning models can forecast airline demand more accurately.
“Machine learning models can more accurately forecast demand”
Listen at 4:10
AI pricing technology could raise fares on busy airline routes.
“The technology could lead to higher fares on busy routes”
Listen at 4:25
AI pricing technology may lower fares on off-peak, low-demand routes.
“but may also result in lower fares on off peak and lower demand routes.”
Listen at 4:31
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Artificial IntelligenceBooks & mentions
Listen to the full episode and explore every guest, topic, and moment on PodLume.